2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2586

Clinical Characteristics and Survival in Systemic Sclerosis-mixed Connective Tissue Disease and Systemic Sclerosis-overlap Syndrome
Abstract Number: 1700

Clinical Characteristics and the Level Disease Activity of Behcet´s Disease in China: A Study Based on Smart System of Disease Management (SSDM)
Abstract Number: 1480

Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 2641

Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Abstract Number: 673

Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center
Abstract Number: 1467

Clinical Characteristics of Primary Sjögren’s Syndrome in Adult Patients Diagnosed at Age Less Than or Equal to 35 Years versus Those over 35 Years of Age
Abstract Number: 1868

Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis
Abstract Number: 2757

Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: A Randomised Controlled Trial (HIT)
Abstract Number: 2576

Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Abstract Number: 2725

Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study
Abstract Number: 1262

Clinical Features of Elderly-onset Adult Still’s Disease
Abstract Number: 397

Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia
Abstract Number: 2123

Clinical Features of Prosthetic Joint Infections in Patients with Rheumatic Diseases vs Osteoarthritis
Abstract Number: 302

Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center
Abstract Number: 2581

Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].